This #LiverAwarenessMonth, we're highlighting #Axiomer #RNAEditing and its applications in cholestatic liver diseases. Learn more: bit.ly/4i5SpOM
Curious about how #Axiomer works? Visit: bit.ly/4iiweDL
#CholestaticDisease #LiverHealth
#BiliaryAtresia (BA) is the leading cause of liver transplantation in children. This #LiverAwarenessMonth, we’re highlighting the urgent need for new options for patients and families affected by BA.
Learn more: bit.ly/4ynZ9ME
#RareDisease #RNAEditing #Axiomer
This #LiverAwarenessMonth, we’re raising awareness of #BiliaryAtresia (BA), a rare liver disease that affects newborns and young children.
For more information about BA, visit our website: bit.ly/3VykIN6
#RareDisease #PediatricLiverDisease #Axiomer #RNAEditing
Starting today at 11a ET. Join us for our virtual Investor & Analyst Educational Event on NTCP modulation in biliary atresia. Details and registration below.
On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.
For additional information about the event and to register, visit: proqr.com/events
#Axiomer #RNAEditing @ProQR
ALT cover slide with text “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing” dated September 30, 2026
ProQR Therapeutics retweeted
On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.
For additional information about the event and to register, visit: proqr.com/events
#Axiomer #RNAEditing @ProQR
ALT cover slide with text “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing” dated September 30, 2026
On Sept 30 at 11a ET join our virtual Investor and Analyst educational event “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing”.
For additional information about the event and to register, visit: proqr.com/events
#Axiomer #RNAEditing @ProQR
ALT cover slide with text “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing” dated September 30, 2026
Axiomer Insights: Our team published findings in Scientific Reports on preclinical liver models for ADAR-mediated RNA editing. Monica from our research team discusses how model selection can inform translatability for our #Axiomer #RNAEditing platform.
bit.ly/3UWJLZz
ProQR welcomes Chris Hart as Chief Data & AI Officer and Thomas Wolf as Strategic AI Advisor to the Board. Their appointments support our strategy to apply AI across discovery and development. AX-0811, the first AI-discovered ProQR program is now in clinical trials.
#Axiomer
To learn more, read the PR: bit.ly/4hGpj8m
And check out the blog on our website: bit.ly/4yaOcyK
Meet Anne Geert from our CMC team! He is responsible for producing the drug substances used in our preclinical and clinical programs. He also helps organize the ProQR conference.
Learn more: bit.ly/4gjPtgA
#Axiomer #TeamProQR
Today we released our Q2 2026 financial results and provided a business update. Read the full press release on our website: bit.ly/45pX5Ic
$PRQR #Biotech #Axiomer #RNAEditing
ProQR has made available a video featuring it’s Management Team discussing the Phase 1 AX-0810 data, the clinical validation of the #Axiomer #RNAEditing platform, AX-0811 and next steps with NTCP.
Watch here: bit.ly/3QZpq4o
Last week, ProQR co-founder Dinko Valerio joined the team to reflect on ProQR’s journey from an ambitious idea to advancing our #Axiomer #RNAEditing platform in the clinic.
We are grateful to Dinko for his contributions over the years and for sharing his passion and insights.
Today is #MPSAwarenessDay.
#Hurlersyndrome is a severe form of MPS and is associated with significant disease burden, impacting quality of life and life expectancy.
We recently announced AX-0422, a potential #RNAEditing therapy in development for Hurler syndrome.
#ShineforMPS
We’re excited to share that ProQR will present new data across multiple scientific conferences this May, highlighting the breadth of our Axiomer™ RNA editing platform.
For more details, check out the PR: bit.ly/42qfJy9
#RNAEditing #Biotech
Drug discovery can be slow and patients are waiting.
Our CEO Daniel de Boer and Ginkgo CEO Jason Kelly sat together to discuss how our collaboration is accelerating our #Axiomer #RNAEditing platform development.
#Biotech #AI
Following our partnership announcement with @Ginkgo Bioworks, our CEO Daniel de Boer sat down with Ginkgo CEO Jason Kelly to discuss the opportunity ahead.
Hear how our #Axiomer #RNAEditing platform, automation, and data can accelerate drug development.
#Biotech #AI
Today we highlighted key updates in our Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810.”
Check out the PR for more details: bit.ly/4tEAbXC and watch the replay of the event: bit.ly/3PZBL7N
#Axiomer #Biotech
In one hour, at 10:00 ET, we are hosting a virtual Investor and Analyst event titled, “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”.
For additional information about the event and to register, visit: lifescievents.com/event/g09g…
#Axiomer #RNAEditing
We’re excited to introduce our partnership with Ginkgo Bioworks and in addition our AI Advisory Board, helping to bring #Axiomer #RNAEditing therapies to patients faster.
Learn more at our Virtual Investor & Analyst event today at 10:00 ET: lifescievents.com/event/g09g…
